AlphAIalphai — Financial news for AI agents
SEC EDGARAUG 291 min read$BIVI

Palumbo Joseph M purchased $10K of BIVI

Palumbo Joseph M (Chief Medical Officer) purchased 4,843 shares of BIOVIE INC. (BIVI) at $2.16 on 2026-08-28.

Original reporting
SEC EDGAR · Palumbo Joseph M
Published Aug 29, 2026, 1:01 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 29, 2026, 1:05 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$BIVI
Neutral
high confidence
Mentioned
$BIVI
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BIVINeutralLow
01

Why it matters

The purchase is modest and unlikely to move the stock, but it confirms insider alignment with shareholders.

02

Market read

Routine insider purchase with limited trading relevance.

03

What to watch

Potential upcoming clinical data or partnership not disclosed in filing.

Relevance 4/10Novelty 3/10Timing: post-market 2026-08-28

Background

Form 4 filings disclose insider transactions; investors monitor for signals of confidence.

Company-level read

Ticker impact

$BIVINeutralHigh confidence
Context

Chief Medical Officer purchased 4,843 shares at $2.16 each, total $10.5K, filing a Form 4 on 2026-08-28.

Expected impact

Minimal short-term price movement expected.

Evidence & confidence

Purchase size is trivial relative to market cap; likely no immediate trading signal.

Market effects

Sector

No broader sector impact; biotech insider activity is routine.

Regional

None

Global

None

Counterpoint

What could challenge this read

Even small insider purchases can precede larger moves if insider has material knowledge.

Key entities

  • Officer
    Palumbo Joseph M

    Chief Medical Officer of BIOVIE INC.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

BIVI insider trading history →

Related articles

AUG 7
$BIVIMedAI 8/10

BioVie stock sinks on Phase IIb Parkinson’s trial data

BioVie (NASDAQ: BIVI) shares fell after Phase IIb Parkinson’s trial data. On Aug. 6 the stock opened 33.3% lower at $1.36, briefly down nearly 60% to $0.82, then closed at $1.35, down 33.8% from Aug. 5. The data were released alongside a filing for a stock offering at $1.33 per share.

yahoo.com4 min
AUG 6
$BIVIMedAI 8/10

BioVie reports positive Phase 2 results for Parkinson's candidate bezisterim

BioVie Inc (NASDAQ:BIVI) reported positive Phase 2 SUNRISE-PD results for its Parkinson's candidate bezisterim. The drug met prespecified endpoints in early-stage, untreated patients, improving blood inflammatory markers and EPNIC-15 versus placebo. Benefits were strongest in patients with higher baseline platelet counts. Safety was similar to placebo, with 39.3% adverse events vs 51.7%.

proactiveinvestors.com4 min
MAY 30
$BIVIMedAI 9/10

BioVie: Long COVID trial fully enrolled – ICYMI

BioVie Inc (NASDAQ:BIVI) said its Phase 2 long COVID trial of bezisterim is fully enrolled, with more than 200 patients randomized to placebo or bezisterim. CEO Cuong Do said the study includes sites such as Yale, Mount Sinai, Mayo Clinic and Stanford, targeting symptoms like brain fog, malaise and fatigue. Top-line results are expected by late October or as early as September; the company plans FDA discussions on accelerated approval or EUA if data support benefit-risk.

proactiveinvestors.com4 min